개방각녹내장에서 라타노프로스틴부노드 0.024%의 단기적 효과, 안정성 및 안구 혈류 변화
Latanoprostene Bunod 0.024% w/v Treatment of Open-anlge Glaucoma: Short-term Effects, Safety, and Changes in Ocular Blood Flow
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 라타노프로스트 0.005% 대비 라타노프로스틴부노드 0.024%의 안압하강, 안구 혈류 개선 효과를 알아보고자 한다. 대상과 방법: 2022년 5월부터 12월까지 라타노프로스트 0.005%를 점안 중인 개방각녹내장 환자 40명을 대상으로 라타노프로스틴부노드 0.024%로 교체하였다. 교체 후 3개월까지 안압, 시력, 시신경유두 주위 혈관밀도, 결막충혈, 각막미란, 눈 주위 색소 침착 및주관적 부작용을 비교하였다. 결과: 라타노프로스틴부노드 0.024% 교체 전과 후 3개월까지 안압은 17.53 ± 6.49 mmHg에서 16.00 ± 8.06 mmHg로 유의하게감소하였다(p=0.032). 최대교정시력은 교체 전과 후 3개월까지 0.24 ± 0.19에서 0.23 ± 0.16으로 유의한 변화가 없었다(p=0.343). 눈 주위 색소 침착은 교체 전과 후 3개월까지 1.16 ± 0.78에서 1.16 ± 0.82로, 점상각막미란은 교체 전과 후 3개월까지 0.58 ± 0.85에서 0.39 ± 0.76으로 유의한 변화가 없었다(각 p=1.000, p=0.050). 결막충혈은 교체 전과 후 3개월까지 1.77 ± 0.88에서 1.42 ± 0.81로 유의하게 감소하였다(p=0.010). Whole image vessel density, peripapillary vessel density는 유의한 변화가 없었다(p>0.05). 부작용은 교체 후 3개월까지 가려움만 유의하게 증가하였다(p=0.008). 결론: 라타노프로스틴부노드 0.024%는 우수한 단기적 안압하강 효과를 보였으나 안구 혈류의 유의한 개선은 없었다.
Abstract
Purpose: To study the short-term intraocular pressure (IOP)-lowering effect and optic nerve head (ONH) blood flow improvement after switching from latanoprost 0.005% w/v to latanoprostene bunod 0.024% w/v. Methods: This prospective study ran from May 2022 to December 2022 and included 40 patients with open-angle glaucoma who switched from latanoprost 0.005% w/v to latanoprostene bunod 0.024% w/v. The IOP, ONH blood flow, and conjunctival hyperemia, corneal erosion, and eyelid pigmentation status were measured 3 months after switching. We recorded all possible side effects. Results: The baseline IOP significantly dropped from 17.53 ± 6.49 to 16.00 ± 8.06 mmHg at 3 months (p = 0.032). The best-corrected visual acuity did not significantly change (0.24 ± 0.19 to 0.23 ± 0.16); neither did eyelid pigmentation (1.16 ± 0.78 to 1.16 ± 0.82) nor the corneal erosion score (0.58 ± 0.85 to 0.39 ± 0.76). Conjunctival hyperemia significantly decreased from 2.00 ± 0.69 to 1.67 ± 0.63 (p = 0.010). Neither the whole-image vessel density nor the peripapillary vessel density significantly changed. However, pruritus became significantly worse after the change (p = 0.008). Conclusions: In the short term, latanoprostene bunod 0.024% w/v lowered the IOP more effectively than did latanoprost 0.005% w/v. However, there was no significant change in ONH blood flow after the switch.
참고문헌 (30)
- Weinreb RN, "The pathophysiology and treatment of glaucoma : a review", JAMA, 311, pp.1901~1911 (2014)
- Kass MA, "The Ocular Hypertension Treatment study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.701~713 (2002)
- Heijl A, "Reduction of intraocular pressure and glaucoma progression : results from the Early Manifest Glaucoma Trial", Arch Ophthalmol, 120, pp.1268~1279 (2002)
- Toris CB, "Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes", Ophthalmology, 100, pp.1297~1304 (1993)
- Nilsson SF, "Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey", Exp Eye Res, 48, pp.707~716 (1989)
- Cavet ME, "The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod : review of nonclinical studies", J Ocul Pharmacol Ther, 34, pp.52~60 (2018)
- Dismuke WM, "Concentrationrelated effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility", Exp Eye Res, 120, pp.28~35 (2014)
- Toda N, "Nitric oxide : ocular blood flow, glaucoma, and diabetic retinopathy", Prog Retin Eye Res, 26, pp.205~238 (2007)
- Harasymowycz P, "Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension : a systematic literature review and a network meta-analysis", Br J Ophthalmol, 106, pp.640~647 (2022)
- Kawase K, "Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study", Adv Ther, 33, pp.1612~1627 (2016)
- Radell JE, "Two-year experience with latanoprostene bunod in clinical practice", J Glaucoma, 30, pp.776~780 (2021)
- Susanna R Jr, "Staging glaucoma patient : why and how?", Open Ophthalmol J, 3, pp.59~64 (2009)
- Gandolfi SA, "Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost", Ophthalmology, 110, pp.609~614 (2003)
- Holló G, "The side effects of the prostaglandin analogues", Expert Opin Drug Saf, 6, pp.45~52 (2007)
- Schulze MM, "The perceived bulbar redness of clinical grading scales", Optom Vis Sci, 86, pp.E1250~8 (2009)
- Bron AJ, "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea, 22, pp.640~650 (2003)
- 이동욱, "비마토프로스트 점안 후 눈 주변 피부 색소침착이 발생한 환자에서 약물중단 후 경과", 대한안과학회지, 48(8), pp.1082~1087 (2007), 대한안과학회
- Rao HL, "Regional comparisons of optical coherence tomography angiography vessel density in primary open-angle glaucoma", Am J Ophthalmol, 171, pp.75~83 (2016)
- Weinreb RN, "A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study", Br J Ophthalmol, 99, pp.738~745 (2015)
- Haefliger IO, "Endothelium-dependent vasoactive modulation in the ophthalmic circulation", Prog Retin Eye Res, 20, pp.209~225 (2001)
- Samaha D, "Effect of latanoprostene bunod on optic nerve head blood flow", Optom Vis Sci, 99, pp.172~176 (2022)
- Polak K, "Altered nitric oxide system in patients with open-angle glaucoma", Arch Ophthalmol, 125, pp.494~498 (2007)
- Astin M, "Role of nitric oxide in PGF2α-induced ocular hyperemia", Exp Eye Res, 59, pp.401~408 (1994)
- Wang Y, "Comparative evaluation of latanoprostene bunod, timolol maleate, and latanoprost ophthalmic solutions to assess their safety and efficacy in lowering intraocular pressure for the management of open-angle glaucoma", Clinics, 75, pp.e1874~ (2020)
- Kim HW, "Periorbital changes associated with prostaglandin analogs in Korean patients", BMC Ophthalmol, 17, pp.126~ (2017)
- Sharpe ED, "The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy", Curr Eye Res, 32, pp.1037~1043 (2007)
- Goldberg I, "Bimatoprost 0.03%", timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%, Br J Ophthalmol, pp.2014, 98[DOI]
- Inoue K, "Adverse periocular reactions to five types of prostaglandin analogs", Eye(Lond), 26, pp.1465~1472 (2012)
- Oogi S, "One-year follow-up study of changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2alfa to omidenepag isopropyl", Cureus, 12, pp.e10064~ (2020)
- Diaconita V, "Washout duration of prostaglandin analogues : a systematic review and meta-analysis", J Ophthalmol, 2018, pp.3190684~ (2018)